Salt Lake City – September 11, 2026 -- A decade-long study by ARUP Laboratories found that 50% of pregnancies with atypical prenatal cell-free DNA (cfDNA) screening results carried at least one clinically significant abnormality confirmed by follow-up testing, reshaping how providers should respond to inconclusive genetic screens.